These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12127620)

  • 21. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
    Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
    Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.
    Geisler T; Anders N; Paterok M; Langer H; Stellos K; Lindemann S; Herdeg C; May AE; Gawaz M
    Diabetes Care; 2007 Feb; 30(2):372-4. PubMed ID: 17259513
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
    Storey RF; Judge HM; Wilcox RG; Heptinstall S
    Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Xiao Z; Théroux P
    J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers.
    Majluf-Cruz A; Chavez-Ochoa AR; Majluf-Cruz K; Coria-Ramirez E; Pineda Del Aguila I; Treviño-Perez S; Matías-Aguilar L; López-Armenta JC; Corona de la Peña N
    Platelets; 2006 Mar; 17(2):105-7. PubMed ID: 16421012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Increased platelet aggregation induced activity by anti-glycoprotein IIb/IIIa antibody in patients with acute coronary syndrome].
    Voskoboĭ IV; Mazurov AV
    Kardiologiia; 2004; 44(10):64-70. PubMed ID: 15477794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
    Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
    Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition.
    Gurbel PA; Bliden KP; Hiatt BL
    J Thromb Haemost; 2003 Jun; 1(6):1319-21. PubMed ID: 12871340
    [No Abstract]   [Full Text] [Related]  

  • 38. A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease.
    Pasqualini L; Pirro M; Lombardini R; Ciuffetti G; Dragani P; Mannarino E
    J Clin Pathol; 2002 Dec; 55(12):946-50. PubMed ID: 12461065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. For how long should treatment with clopidogrel be continued after coronary stent implantation?
    Rozenman Y
    J Am Coll Cardiol; 2004 Apr; 43(7):1331; author reply 1331-2. PubMed ID: 15063450
    [No Abstract]   [Full Text] [Related]  

  • 40. Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients.
    Papp E; Havasi V; Bene J; Komlosi K; Talian G; Feher G; Horvath B; Szapary L; Toth K; Melegh B
    Drugs Aging; 2007; 24(4):345-50. PubMed ID: 17432927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.